このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Glenmark Pharmaceuticals バランスシートの健全性
財務の健全性 基準チェック /46
Glenmark Pharmaceuticalsの総株主資本は₹78.5B 、総負債は₹9.9Bで、負債比率は12.6%となります。総資産と総負債はそれぞれ₹143.6Bと₹65.1Bです。 Glenmark Pharmaceuticalsの EBIT は₹6.1Bで、利息カバレッジ比率1.2です。現金および短期投資は₹16.6Bです。
主要情報
12.6%
負債資本比率
₹9.91b
負債
| インタレスト・カバレッジ・レシオ | 1.2x |
| 現金 | ₹16.59b |
| エクイティ | ₹78.48b |
| 負債合計 | ₹65.11b |
| 総資産 | ₹143.59b |
財務の健全性に関する最新情報
Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16
Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20Recent updates
Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value
May 08Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Jan 18We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Dec 13Estimating The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Oct 10財務状況分析
短期負債: GLENMARKの 短期資産 ( ₹74.3B ) が 短期負債 ( ₹58.2B ) を超えています。
長期負債: GLENMARKの短期資産 ( ₹74.3B ) が 長期負債 ( ₹6.9B ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: GLENMARK総負債よりも多くの現金を保有しています。
負債の削減: GLENMARKの負債対資本比率は、過去 5 年間で79.4%から12.6%に減少しました。
債務返済能力: GLENMARKの 営業キャッシュフロー はマイナスであるため、負債は十分にカバーされていません。
インタレストカバレッジ: GLENMARKの負債に対する 利息支払い は EBIT ( 1.2 x coverage) によって 十分にカバーされていません。